XTX Topco Ltd Sells 3,557 Shares of Amgen Inc. (NASDAQ:AMGN)

XTX Topco Ltd cut its stake in Amgen Inc. (NASDAQ:AMGN) by 60.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,345 shares of the medical research company’s stock after selling 3,557 shares during the period. XTX Topco Ltd’s holdings in Amgen were worth $611,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new position in Amgen in the fourth quarter valued at approximately $25,000. Ritter Daniher Financial Advisory LLC DE increased its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in Amgen in the 4th quarter valued at approximately $34,000. Atala Financial Inc acquired a new stake in Amgen in the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the fourth quarter worth $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 1.9 %

NASDAQ:AMGN opened at $277.29 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $149.09 billion, a PE ratio of 36.73, a PEG ratio of 2.63 and a beta of 0.59. The firm has a 50-day moving average of $303.04 and a 200-day moving average of $294.22.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio is 126.09%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AMGN shares. Truist Financial cut their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. UBS Group lifted their target price on shares of Amgen from $315.00 to $319.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Finally, Piper Sandler boosted their price objective on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average target price of $314.91.

Insider Transactions at Amgen

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last quarter. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.